Viatris Financial Ratios
NASDAQ: VTRSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Viatris ratio analysis
Viatris earned a net margin of -24.6% in FY 2025, down from -4.3% a year earlier. Gross margin was 35.1% compared with a median of 35.0% over the prior 7 years. Return on equity reached -23.9%, meaning Viatris generated -0.24 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.98 versus 0.75 the year before, and the current ratio was 1.38. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Viatris financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | 216.60 | 6.51 | — | — | 673.33 | 42.41 |
| Price / sales | — | — | 0.84 | 0.83 | 0.91 | 0.94 | 0.91 | 1.30 |
| Price / book | — | — | 0.64 | 0.64 | 0.80 | 0.49 | — | 1.22 |
| Gross margin | 35.1% | 38.2% | 41.7% | 40.0% | 31.2% | 31.8% | 33.9% | 35.0% |
| Operating margin | -18.6% | 0.1% | 5.0% | 9.9% | -0.2% | -1.8% | 6.2% | 7.9% |
| Net margin | -24.6% | -4.3% | 0.4% | 12.8% | -7.1% | -5.6% | 0.1% | 3.1% |
| Free cash flow margin | 13.5% | 13.4% | 16.4% | 15.9% | 14.3% | 8.3% | 13.8% | 18.3% |
| Return on equity (ROE) | -23.9% | -3.4% | 0.3% | 9.9% | -6.2% | -2.9% | — | 2.9% |
| Return on assets (ROA) | -9.5% | -1.5% | 0.1% | 4.2% | -2.3% | -1.1% | 0.1% | — |
| Debt / equity | 0.98 | 0.75 | 0.89 | 0.91 | 1.05 | 1.08 | — | — |
| Current ratio | 1.38 | 1.65 | 1.67 | 1.58 | 1.10 | 1.22 | 1.21 | — |
| Revenue growth | -3.0% | -4.5% | -5.1% | -9.1% | 49.7% | 3.9% | 0.6% | — |
| EPS growth | — | -1,160.0% | -97.1% | — | — | -3,800.0% | -95.6% | — |